Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy

As adjuvant chemotherapy (AC) for soft tissue sarcomas is controversial, we performed a retrospective analysis of patients seen at Washington University in St. Louis to evaluate whether it benefited our patient population. Patients were risk-assessed using the Memorial Sloan Kettering Predictive Nom...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Schenone, Aaron D, Luo, Jingqin, Montgomery, Luke, Morgensztern, Daniel, Adkins, Douglas R, Van Tine, Brian A
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: BlackWell Publishing Ltd 2014
विषय:
Original Research
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4101751/
https://ncbi.nlm.nih.gov/pubmed/24574357
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.209
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन